Prediction of sensitivity to gefitinib/ erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis

Non-small cell lung cancer (NSCLC) with activating EGFR mutations, especially exon 19 deletions and the L858R point mutation, is particularly responsive to gefitinib and erlotinib. However, the sensitivity varies for less common and rare EGFR mutations.